Sinovac Completes Immunization Schedule in the Phase I Clinical Trial of its Proprietary Avian Influenza Vaccine (H5N1)

2006-04-11

Sinovac Completes Immunization Schedule in the Phase I Clinical Trial of its Proprietary Avian Influenza Vaccine (H5N1)

Beijing , April 10, 2006 (Xinhua PR Newswire) -- Sinovac Biotech Ltd. (AMEX: SVA) announced today that all 120 volunteers in the Phase I clinical trial of its avian influenza vaccine (H5N1) have completed the two shot regimen of either the vaccine or a placebo.

All 120 volunteers (aged 18 - 60 years) in the clinical trial were thoroughly evaluated and medically documented prior to entering the vaccination program. The clinical trial was conducted on a 0 and 28 day dose immunization schedule. Sinovac expects to take blood samples from volunteers to analyze the antibody growth and effectiveness of the vaccine.

Sinovac’s CEO, Mr. Weidong Yin commented, “Everything is progressing as we expected. Teaming up with the China CDC is extremely beneficial. We are working hard together to produce a safe and effective vaccine that I believe will benefit the whole world.”

About Sinovac

Sinovac Biotech Ltd. is a world-class Chinese biopharmaceutical company, focused on research, development and commercialization of vaccines designed to combat human infectious diseases. Sinovac’s vaccines include Healive™ (hepatitis A), Bilive™ (hepatitis B) and Anflu™ (influenza). Sinovac has vaccines in clinical trials to combat avian influenza (bird flu) and SARS.

Additional information about Sinovac is available on the Company website, http://www.sinovac.com and the Sinovac Investor Relations website, http://finance.groups.yahoo.com/group/Sinovac_Biotech_IR/

To be added to our distribution list, please email: info@sinovac.com

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

CONTACT:

Craig H. Bird

Segue Investor Relations

(215) 782 - 8682

Toll Free: 1-866-360-8682 (

North America)

Email: sinovac@verizon.net

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com